Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: neuropsychiatrie 2/2014

01.06.2014 | case report

Detecting and treating adult attention deficit hyperactivity disorder in a patient with schizophrenia

verfasst von: MD Julia Huemer, Ingrid Sibitz

Erschienen in: neuropsychiatrie | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten
share
TEILEN

Summary

Background

The comorbidity of attention deficit hyperactivity disorder (ADHD) and schizophrenia poses a considerable diagnostic challenge due to significant symptom overlap, and represents a highly debilitating condition for the patient. This case report aims to present the history of a 19-year-old patient suffering from these two diagnostic entities, and thereby seeks to elucidate diagnostic and therapeutic approaches for this condition.

Methods

The Diagnostic and Statistical Manual of Mental Disorders (fourth edition) criteria for ADHD and schizophrenia were used to establish clinical diagnoses. Furthermore, an in-depth clinical interview with the patient’s mother was carried out. Finally, a clinical interview was conducted with the patient and the Wender Utah Rating Scale was applied to assess ADHD symptoms retrospectively.

Results

Outcomes of the mentioned diagnostic approaches confirmed the diagnosis of ADHD in the patient suffering from schizophrenia. As amphetamines would be contraindicated in the described patient, atomoxetine, a drug approved for the treatment of ADHD due to its efficacy as a selective norepinephrine reuptake inhibitor, was chosen. Following a 6-week interval after treatment initiation, a clinical re-evaluation was carried out, which showed an improvement of symptoms according to the International Classification of Diseases (tenth revision) criteria.

Conclusion

The present case report indicates that atomoxetine may be effective in treating symptoms of ADHD in patients with schizophrenia, without increasing psychotic symptoms. Results are discussed in terms of diagnostic and therapeutic implications.
Literatur
1.
Zurück zum Zitat Kooij SJ, Bejerot S, Blackwell A, et al. European consensus statement on diagnosis and treatment of adult ADHD: the European Network Adult ADHD. BMC Psychiatry. 2010;10:67. PubMedCentralPubMedCrossRef Kooij SJ, Bejerot S, Blackwell A, et al. European consensus statement on diagnosis and treatment of adult ADHD: the European Network Adult ADHD. BMC Psychiatry. 2010;10:67. PubMedCentralPubMedCrossRef
2.
Zurück zum Zitat Hill JC, Schoener EP. Age-dependent decline of attention deficit hyperactivity disorder. Am J Psychiatry. 1996;153(9):1143–6. PubMed Hill JC, Schoener EP. Age-dependent decline of attention deficit hyperactivity disorder. Am J Psychiatry. 1996;153(9):1143–6. PubMed
3.
Zurück zum Zitat Faraone SV, Biederman J, Mick E. The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies. Psychol Med. 2006;36(2):159–65. PubMedCrossRef Faraone SV, Biederman J, Mick E. The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies. Psychol Med. 2006;36(2):159–65. PubMedCrossRef
4.
Zurück zum Zitat Simon V, Czobor P, Balint S, Meszaros A, Bitter I. Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis. Br J Psychiatry. 2009;194(3):204–11. PubMedCrossRef Simon V, Czobor P, Balint S, Meszaros A, Bitter I. Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis. Br J Psychiatry. 2009;194(3):204–11. PubMedCrossRef
5.
Zurück zum Zitat Sandra Kooij JJ, Marije Boonstra A, Swinkels SH, Bekker EM, de Noord I, Buitelaar JK. Reliability, validity, and utility of instruments for self-report and informant report concerning symptoms of ADHD in adult patients. J Atten Disord. 2008;11(4):445–58. PubMedCrossRef Sandra Kooij JJ, Marije Boonstra A, Swinkels SH, Bekker EM, de Noord I, Buitelaar JK. Reliability, validity, and utility of instruments for self-report and informant report concerning symptoms of ADHD in adult patients. J Atten Disord. 2008;11(4):445–58. PubMedCrossRef
6.
Zurück zum Zitat Prince JB. Pharmacotherapy of attention-deficit hyperactivity disorder in children and adolescents: update on new stimulant preparations, atomoxetine, and novel treatments. Child Adolesc Psychiatr Clin N Am. 2006;15(1):13–50. PubMedCrossRef Prince JB. Pharmacotherapy of attention-deficit hyperactivity disorder in children and adolescents: update on new stimulant preparations, atomoxetine, and novel treatments. Child Adolesc Psychiatr Clin N Am. 2006;15(1):13–50. PubMedCrossRef
7.
Zurück zum Zitat Meszaros A, Czobor P, Balint S, Komlosi S, Simon V, Bitter I. Pharmacotherapy of adult attention deficit hyperactivity disorder (ADHD): a meta-analysis. Int J Neuropsychopharmacol. 2009;12(8):1137–47. PubMedCrossRef Meszaros A, Czobor P, Balint S, Komlosi S, Simon V, Bitter I. Pharmacotherapy of adult attention deficit hyperactivity disorder (ADHD): a meta-analysis. Int J Neuropsychopharmacol. 2009;12(8):1137–47. PubMedCrossRef
8.
Zurück zum Zitat Biederman J. Impact of comorbidity in adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2004;65(Suppl. 3):3–7. PubMed Biederman J. Impact of comorbidity in adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2004;65(Suppl. 3):3–7. PubMed
9.
Zurück zum Zitat Hallerbäck MU, Lugnegård T, Gillberg C. ADHD and nicotine use in schizophrenia and Asperger syndrome: a controlled study. J Atten Disord. 2012. Epub ahead of print. Hallerbäck MU, Lugnegård T, Gillberg C. ADHD and nicotine use in schizophrenia and Asperger syndrome: a controlled study. J Atten Disord. 2012. Epub ahead of print.
10.
Zurück zum Zitat Donev R, Gantert D, Alawam K, et al. Comorbidity of schizophrenia and adult attention-deficit hyperactivity disorder. World J Biol Psychiatry. 2011;12(Suppl. 1):52–6. PubMed Donev R, Gantert D, Alawam K, et al. Comorbidity of schizophrenia and adult attention-deficit hyperactivity disorder. World J Biol Psychiatry. 2011;12(Suppl. 1):52–6. PubMed
11.
12.
Zurück zum Zitat Ward MF, Wender PH, Reimherr FW. The Wender Utah Rating Scale: an aid in the retrospective diagnosis of childhood attention deficit hyperactivity disorder. Am J Psychiatry. 1993;150(6):885–90. PubMed Ward MF, Wender PH, Reimherr FW. The Wender Utah Rating Scale: an aid in the retrospective diagnosis of childhood attention deficit hyperactivity disorder. Am J Psychiatry. 1993;150(6):885–90. PubMed
13.
Zurück zum Zitat Havik B, Degenhardt FA, Johansson S, et al. DCLK1 variants are associated across schizophrenia and attention deficit/hyperactivity disorder. PLoS One. 2012;7(4):e35424. PubMedCentralPubMedCrossRef Havik B, Degenhardt FA, Johansson S, et al. DCLK1 variants are associated across schizophrenia and attention deficit/hyperactivity disorder. PLoS One. 2012;7(4):e35424. PubMedCentralPubMedCrossRef
14.
Zurück zum Zitat Peralta V, de Jalon EG, Campos MS, Zandio M, Sanchez-Torres A, Cuesta MJ. The meaning of childhood attention-deficit hyperactivity symptoms in patients with a first-episode of schizophrenia-spectrum psychosis. Schizophr Res. 2011;126(1–3):28–35. PubMedCrossRef Peralta V, de Jalon EG, Campos MS, Zandio M, Sanchez-Torres A, Cuesta MJ. The meaning of childhood attention-deficit hyperactivity symptoms in patients with a first-episode of schizophrenia-spectrum psychosis. Schizophr Res. 2011;126(1–3):28–35. PubMedCrossRef
15.
Zurück zum Zitat Kraemer M, Uekermann J, Wiltfang J, Kis B. Methylphenidate-induced psychosis in adult attention-deficit/hyperactivity disorder: report of 3 new cases and review of the literature. Clin Neuropharmacol. 2010;33(4):204–6. PubMedCrossRef Kraemer M, Uekermann J, Wiltfang J, Kis B. Methylphenidate-induced psychosis in adult attention-deficit/hyperactivity disorder: report of 3 new cases and review of the literature. Clin Neuropharmacol. 2010;33(4):204–6. PubMedCrossRef
16.
Zurück zum Zitat Bymaster FP, Katner JS, Nelson DL, et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology. 2002;27(5):699–711. PubMedCrossRef Bymaster FP, Katner JS, Nelson DL, et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology. 2002;27(5):699–711. PubMedCrossRef
17.
Zurück zum Zitat Tossell JW, Greenstein DK, Davidson AL, et al. Stimulant drug treatment in childhood-onset schizophrenia with comorbid ADHD: an open-label case series. J Child Adolesc Psychopharmacol. 2004;14(3):448–54. PubMedCrossRef Tossell JW, Greenstein DK, Davidson AL, et al. Stimulant drug treatment in childhood-onset schizophrenia with comorbid ADHD: an open-label case series. J Child Adolesc Psychopharmacol. 2004;14(3):448–54. PubMedCrossRef
Metadaten
Titel
Detecting and treating adult attention deficit hyperactivity disorder in a patient with schizophrenia
verfasst von
MD Julia Huemer
Ingrid Sibitz
Publikationsdatum
01.06.2014
Verlag
Springer Vienna
Erschienen in
neuropsychiatrie / Ausgabe 2/2014
Print ISSN: 0948-6259
Elektronische ISSN: 2194-1327
DOI
https://doi.org/10.1007/s40211-014-0103-0